220 related articles for article (PubMed ID: 38383558)
1. Orthogonal inducible control of Cas13 circuits enables programmable RNA regulation in mammalian cells.
Ding Y; Tous C; Choi J; Chen J; Wong WW
Nat Commun; 2024 Feb; 15(1):1572. PubMed ID: 38383558
[TBL] [Abstract][Full Text] [Related]
2. Orthogonal inducible control of Cas13 circuits enables programmable RNA regulation in mammalian cells.
Ding Y; Tous C; Choi J; Chen J; Wong WW
bioRxiv; 2023 Mar; ():. PubMed ID: 36993327
[TBL] [Abstract][Full Text] [Related]
3. Cas13d: A New Molecular Scissor for Transcriptome Engineering.
Gupta R; Ghosh A; Chakravarti R; Singh R; Ravichandiran V; Swarnakar S; Ghosh D
Front Cell Dev Biol; 2022; 10():866800. PubMed ID: 35433685
[TBL] [Abstract][Full Text] [Related]
4. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects.
Tong H; Huang J; Xiao Q; He B; Dong X; Liu Y; Yang X; Han D; Wang Z; Wang X; Ying W; Zhang R; Wei Y; Xu C; Zhou Y; Li Y; Cai M; Wang Q; Xue M; Li G; Fang K; Zhang H; Yang H
Nat Biotechnol; 2023 Jan; 41(1):108-119. PubMed ID: 35953673
[TBL] [Abstract][Full Text] [Related]
5. Repurposing CRISPR-Cas13 systems for robust mRNA trans-splicing.
Fiflis DN; Rey NA; Venugopal-Lavanya H; Sewell B; Mitchell-Dick A; Clements KN; Milo S; Benkert AR; Rosales A; Fergione S; Asokan A
Nat Commun; 2024 Mar; 15(1):2325. PubMed ID: 38485709
[TBL] [Abstract][Full Text] [Related]
6. The effects of length and sequence of gRNA on Cas13b and Cas13d activity in vitro and in vivo.
Liu Y; Jing P; Zhou Y; Zhang J; Shi J; Zhang M; Yang H; Fei J
Biotechnol J; 2023 Sep; 18(9):e2300002. PubMed ID: 37148478
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells.
Ai Y; Liang D; Wilusz JE
Nucleic Acids Res; 2022 Jun; 50(11):e65. PubMed ID: 35244715
[TBL] [Abstract][Full Text] [Related]
8. Programmable RNA base editing with photoactivatable CRISPR-Cas13.
Yu J; Shin J; Yu J; Kim J; Yu D; Heo WD
Nat Commun; 2024 Jan; 15(1):673. PubMed ID: 38253589
[TBL] [Abstract][Full Text] [Related]
9. Optimization of specific RNA knockdown in mammalian cells with CRISPR-Cas13.
Burris BJD; Molina Vargas AM; Park BJ; O'Connell MR
Methods; 2022 Oct; 206():58-68. PubMed ID: 35987443
[TBL] [Abstract][Full Text] [Related]
10. Negative autoregulation mitigates collateral RNase activity of repeat-targeting CRISPR-Cas13d in mammalian cells.
Kelley CP; Haerle MC; Wang ET
Cell Rep; 2022 Aug; 40(7):111226. PubMed ID: 35977479
[TBL] [Abstract][Full Text] [Related]
11. The double life of CRISPR-Cas13.
Bot JF; van der Oost J; Geijsen N
Curr Opin Biotechnol; 2022 Dec; 78():102789. PubMed ID: 36115160
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic targeting of host RNA by Cas13 constrains its utility.
Li Z; Li Z; Cheng X; Wang S; Wang X; Ma S; Lu Z; Zhang H; Zhao W; Chen Z; Yao Y; Zhang C; Chao L; Li W; Fei T
Nat Biomed Eng; 2024 Feb; 8(2):177-192. PubMed ID: 37872368
[TBL] [Abstract][Full Text] [Related]
13. Photoactivatable RNA N
Zhao J; Li B; Ma J; Jin W; Ma X
Small; 2020 Jul; 16(30):e1907301. PubMed ID: 32583968
[TBL] [Abstract][Full Text] [Related]
14. Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family.
Liu L; Pei DS
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232699
[TBL] [Abstract][Full Text] [Related]
15. Deep learning and CRISPR-Cas13d ortholog discovery for optimized RNA targeting.
Wei J; Lotfy P; Faizi K; Baungaard S; Gibson E; Wang E; Slabodkin H; Kinnaman E; Chandrasekaran S; Kitano H; Durrant MG; Duffy CV; Pawluk A; Hsu PD; Konermann S
Cell Syst; 2023 Dec; 14(12):1087-1102.e13. PubMed ID: 38091991
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas13 Precision Transcriptome Engineering in Cancer.
Granados-Riveron JT; Aquino-Jarquin G
Cancer Res; 2018 Aug; 78(15):4107-4113. PubMed ID: 30021724
[TBL] [Abstract][Full Text] [Related]
17. Advances in CRISPR-Cas systems for RNA targeting, tracking and editing.
Wang F; Wang L; Zou X; Duan S; Li Z; Deng Z; Luo J; Lee SY; Chen S
Biotechnol Adv; 2019; 37(5):708-729. PubMed ID: 30926472
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas13 technology portfolio and alliance with other genetic tools.
Wu S; Tian P; Tan T
Biotechnol Adv; 2022 Dec; 61():108047. PubMed ID: 36208845
[TBL] [Abstract][Full Text] [Related]
19. Applications of the versatile CRISPR-Cas13 RNA targeting system.
Kordyś M; Sen R; Warkocki Z
Wiley Interdiscip Rev RNA; 2022 May; 13(3):e1694. PubMed ID: 34553495
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research.
Palaz F; Kalkan AK; Can Ö; Demir AN; Tozluyurt A; Özcan A; Ozsoz M
ACS Synth Biol; 2021 Jun; 10(6):1245-1267. PubMed ID: 34037380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
